Simufilam is SAVA’s proprietary, investigational oral small molecule that targets the filamin A protein. Cassava released top-line results from the phase III REFOCUS-ALZ study, which evaluated ...

A downtrend has been apparent in Cassava Sciences, Inc. (SAVA) lately with too much selling ... are majorly in agreement about the company's ability to report better earnings than they predicted ...

SAVA isn't done with simufilam in Alzheimer's disease, the company is set to report results from REFOCUS-ALZ in late Q1'25 or early Q2'25. SAVA had $128.6M in cash and cash equivalents at the end ...